We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-1.18%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$496M
AUM Growth
+$22M
(+4.6%)
Cap. Flow
+$34.5M
Cap. Flow
% of AUM
6.96%
Top 10 Holdings %
Top 10 Hldgs %
10.47%
Holding
461
New
27
Increased
142
Reduced
189
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$3.17M |
| 2 |
MPLX
MPLX
|
+$3.04M |
| 3 |
BlackRock Limited Duration Income Trust
BLW
|
+$2.79M |
| 4 |
ABDC
Alcentra Capital Corp
ABDC
|
+$1.98M |
| 5 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$1.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
+$6.67M |
| 2 |
ECC
Eagle Point Credit Company
ECC
|
+$5.43M |
| 3 |
ANDX
Andeavor Logistics LP
ANDX
|
+$2.66M |
| 4 |
BlackRock Floating Rate Income Strategies Fund
FRA
|
+$2.25M |
| 5 |
MVC
MVC Capital, Inc.
MVC
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.1% |
| 2 | Real Estate | 16.28% |
| 3 | Energy | 14.42% |
| 4 | Healthcare | 8.59% |
| 5 | Materials | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Geron
GERN
$911M
| $226K | 0.05% |
169,567
-9,445
| -5% | -$12.7K |
|
227
Axsome Therapeutics
AXSM
$12.4B
| $224K | 0.05% |
11,076
-616
| -5% | -$15.8K |
|
228
Madrigal Pharmaceuticals
MDGL
$12.6B
| $224K | 0.05% |
2,600
-144
| -5% | -$13.5K |
|
|
EPZM
229
DELISTED
Epizyme, Inc
EPZM
| $224K | 0.05% |
21,720
-1,210
| -5% | -$15.3K |
|
|
GRTS
230
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $222K | 0.04% |
25,698
-1,432
| -5% | -$14.5K |
|
231
Viking Therapeutics
VKTX
$4.04B
| $221K | 0.04% |
32,151
-1,790
| -5% | -$13.3K |
|
|
ARQL
232
DELISTED
Arqule Inc
ARQL
| $221K | 0.04% |
30,806
-1,716
| -5% | -$16.1K |
|
233
Fate Therapeutics
FATE
$281M
| $220K | 0.04% |
14,176
-789
| -5% | -$15.1K |
|
234
BioCryst Pharmaceuticals
BCRX
$2.37B
| $214K | 0.04% |
74,533
-4,151
| -5% | -$12.9K |
|
235
PTC Therapeutics
PTCT
$6.37B
| $213K | 0.04% |
6,308
-352
| -5% | -$15.3K |
|
236
MacroGenics
MGNX
$235M
| $212K | 0.04% |
16,594
-925
| -5% | -$13.3K |
|
237
Prothena Corp
PRTA
$458M
| $211K | 0.04% |
26,882
-1,497
| -5% | -$13.3K |
|
|
MRTX
238
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $210K | 0.04% |
2,690
-149
| -5% | -$14K |
|
|
CLVS
239
DELISTED
Clovis Oncology, Inc.
CLVS
| $210K | 0.04% |
53,505
-9,004
| -14% | -$72.8K |
|
|
ARNA
240
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $210K | 0.04% |
4,584
-254
| -5% | -$14.3K |
|
241
Gossamer Bio
GOSS
$66.5M
| $209K | 0.04% |
12,473
-695
| -5% | -$13.8K |
|
242
Denali Therapeutics
DNLI
$3.67B
| $207K | 0.04% |
13,494
-752
| -5% | -$14.4K |
|
243
Alaunos Therapeutics
TCRT
$4.74M
| $207K | 0.04% |
323
-18
| -5% | -$14.3K |
|
244
Kura Oncology
KURA
$922M
| $206K | 0.04% |
13,566
-756
| -5% | -$13.5K |
|
|
CBAY
245
DELISTED
Cymabay Therapeutics
CBAY
| $206K | 0.04% |
40,232
-2,241
| -5% | -$13.6K |
|
|
ORTX
246
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $206K | 0.04% |
1,737
-96
| -5% | -$13.4K |
|
|
PRNB
247
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $206K | 0.04% |
7,294
-406
| -5% | -$14.9K |
|
|
BPMC
248
DELISTED
Blueprint Medicines
BPMC
| $205K | 0.04% |
2,796
-155
| -5% | -$13.4K |
|
|
CCXI
249
DELISTED
ChemoCentryx, Inc.
CCXI
| $205K | 0.04% |
30,286
-1,687
| -5% | -$12.7K |
|
|
AUTL
250
Autolus Therapeutics
AUTL
$386M
| $204K | 0.04% |
16,398
-913
| -5% | -$12.1K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q3 2019 Portfolio in Review
As of Q3 2019, Virtus ETF Advisers held 461 positions worth $496M, up 4.6% from $474M the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Virtus ETF Advisers deployed $34.5M of net new capital in Q3 2019, opening 27 new positions and adding to 142 existing holdings. Its largest new stake was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.
By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 24% a quarter earlier, followed by Real Estate and Energy.
On the sell side, the largest reduction was TriplePoint Venture Growth BDC, an estimated $813K trimmed.
- Virtus ETF Advisers's largest Q3 2019 buy was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.
- Virtus ETF Advisers added most to MPLX in Q3 2019, an estimated $3.04M increase.
- Virtus ETF Advisers's biggest Q3 2019 reduction was TriplePoint Venture Growth BDC, cutting an estimated $813K.
- Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2019, selling an estimated $6.67M.
- Virtus ETF Advisers's ten largest holdings make up 10% of its $496M portfolio in Q3 2019.
- Virtus ETF Advisers opened 27 new positions and closed 26 in Q3 2019.
- Virtus ETF Advisers's portfolio value rose 4.6% quarter-over-quarter to $496M.
Based on Virtus ETF Advisers's 13F filing for Q3 2019, filed 12 Nov 2019.